

Resource Summary Report

Generated by [nidm-terms](#) on Aug 16, 2026

Pacific Blue(TM) anti-human CD8

RRID:AB_10551438

Type: Antibody

Proper Citation

BioLegend Cat# 344718, RRID:AB_10551438

Antibody Information

URL: http://antibodyregistry.org/AB_10551438

Proper Citation: BioLegend Cat# 344718, RRID:AB_10551438

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Pacific Blue(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_10551438

Vendor: BioLegend

Catalog Number: 344718

Alternative Catalog Numbers: 344717

Record Creation Time: 20250819T230824+0000

Record Last Update: 20250820T042449+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue(TM) anti-human CD8.

No alerts have been found for Pacific Blue(TM) anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Bajgain P, et al. (2026) Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. *Cell reports. Medicine*, 7(5), 102782.

Wang J, et al. (2026) EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation. *Cell*.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Malmström E, et al. (2025) Human proteome distribution atlas for tissue-specific plasma proteome dynamics. *Cell*, 188(10), 2810.

Zhao Z, et al. (2025) Sick cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Jelcic I, et al. (2025) T-bet+ CXCR3+ B cells drive hyperreactive B-T cell interactions in multiple sclerosis. *Cell reports. Medicine*, 6(3), 102027.

Hu Y, et al. (2024) Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity. *Cell reports. Medicine*, 5(5), 101530.

Tan J, et al. (2024) STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity. *EBioMedicine*, 101, 105035.

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. *Cell*, 187(11), 2817.

Ramakrishnan A, et al. (2024) Epigenetic dysregulation in Alzheimer's disease peripheral immunity. *Neuron*.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target. *Cell*, 187(11), 2703.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

Obradovic A, et al. (2021) Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. *Cell*, 184(11), 2988.

German Y, et al. (2021) Morphological profiling of human T and NK lymphocytes by high-content cell imaging. *Cell reports*, 36(1), 109318.

Li Y, et al. (2020) Co-culture Systems of Drug-Treated Acute Myeloid Leukemia Cells and T Cells for In Vitro and In Vivo Study. *STAR protocols*, 1(2).

Zhang C, et al. (2020) STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth. *Cell metabolism*, 31(1), 148.

Wang J, et al. (2020) HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. *Cell*, 183(5), 1264.